

Special Issue

HIV Therapy: The Latest Developments in Antiviral Drugs

Message from the Guest Editor

This Special Issue, "HIV Therapy: The Latest Developments in Antiviral Drugs", aims to collate cutting-edge experimental and laboratory research on HIV treatments. Despite significant advancements in antiretroviral therapy (ART), challenges such as drug resistance, long-term toxicity, and the quest for a functional cure or eradication necessitate continuous innovation. We invite contributions that delve into novel antiviral agents, including small molecules and biologics; their mechanisms of action; and innovative therapeutic strategies. Emphasis will be placed on preclinical studies, in vitro and ex vivo models, the virological and immunological mechanisms underlying new therapies, novel drug delivery systems explored at the laboratory level, and approaches to understanding and targeting HIV reservoirs. This Special Issue will highlight basic and translational research that underpins the development of next-generation HIV therapies, focusing on the molecular, cellular, and immunological insights that will pave the way for future clinical applications. We welcome original research articles and comprehensive reviews that fit within this experimental medicine framework.

Guest Editor

Dr. Francisco Javier Fanjul Losa

Infectious Diseases Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain

Deadline for manuscript submissions

31 December 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/242263

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).